Eikon Therapeutics Inc. logo

Eikon Therapeutics (EIKN) stock

EIKN · Eikon Therapeutics Inc. · NASDAQ

Market cap
$257.9M
Shares out
54.2M

What is the latest news on EIKN stock?

PRago
Eikon Therapeutics Announces Clearance to Proceed with First-in-Human Phase 1/2 Study for Novel Androgen Receptor Antagonist EIK1006 in Advanced Metastatic Prostate Cancer

Internally-derived candidate EIK1006 targets wild-type androgen receptor and clinically relevant variants implicated in resistance to conventional prostate cancer therapiesInitial clinical data from Phase 1/2 study expected in second half of 2027 MILLBRAE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (NASDAQ:EIKN) ("Eikon"), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced U.S. Food and Drug Administration clearance to proceed for the Investigational New Drug (IND) application to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer.  Eikon plans t

All EIKN news

When does Eikon Therapeutics report earnings?

The latest Eikon Therapeutics earnings release came out on Nov 12, 2026: Eikon Therapeutics Reports Third Quarter 2026 Financial Results and Provides Clinical Updates.

EIKN earnings history

Who owns the most EIKN stock?

FMR LLC was the largest reported holder of EIKN at the end of Q2 2026, with 4,993,906 shares worth $65.2 million. Next came BlackRock, Inc. ($55.9 million) and Foresite Capital Management IV, LLC ($25.4 million). In all, 77 institutions reported $344.3 million of EIKN in their 13F filings.

All EIKN fund holders

Are insiders buying or selling EIKN?

Insiders are buying. In the last 90 days 1 insider bought $1.0 million of EIKN in trades reported on Form 4. The latest: Column Group IV GP, LP bought $1.0 million, reported on Sep 8, 2026.

EIKN insider trades

Latest news

25 items

EIKN rankings

News · 26 weeks340%
2026-05-24: 12026-05-31: 12026-06-07: 22026-06-14: 12026-06-21: 12026-06-28: 02026-07-05: 02026-07-12: 02026-07-19: 12026-07-26: 12026-08-02: 22026-08-09: 62026-08-16: 12026-08-23: 12026-08-30: 12026-09-06: 12026-09-13: 02026-09-20: 02026-09-27: 12026-10-04: 12026-10-11: 22026-10-18: 32026-10-25: 22026-11-01: 12026-11-08: 32026-11-15: 1
2026-05-242026-11-15
Mix1790d
  • Other9(53%)
  • SEC Filings4(24%)
  • Leadership1(6%)
  • Insider1(6%)
  • Analyst1(6%)
  • Earnings1(6%)
Activity · 52 weeks6842 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Eikon Therapeutics Inc. (EIKN) is a Biotechnology: Biological Products (No Diagnostic Substances) company listed on NASDAQ. In the last 30 days Quantisnow tracked 9 wire items for EIKN, including 4 press releases and news items, 4 SEC filings and 1 earnings update. The most recent was published Nov 17, 2026.

EIKN FAQ

6 questions
  • Where does EIKN stock trade?
    Eikon Therapeutics Inc. (EIKN) is listed on NASDAQ.
  • What sector and industry is EIKN in?
    Eikon Therapeutics Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.
  • When did Eikon Therapeutics Inc. go public?
    Eikon Therapeutics Inc. (EIKN) completed its IPO in 2026.
  • What are analysts saying about EIKN?
    Eikon Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $23.00 price target on 2026-10-16. Recent price targets range from $7.00 to $34.00.
  • What companies are similar to EIKN?
    Notable peers in the same industry include RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.), MRNA (Moderna Inc.), GILD (Gilead Sciences Inc.), AMGN (Amgen Inc.). Compare EIKN side-by-side with any of them on Quantisnow.
  • How can I track EIKN on Quantisnow?
    Quantisnow aggregates Eikon Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EIKN to receive live email and push alerts on every new disclosure.

Is something on this page wrong, or out of date? Request a change